$349 Million is the total value of GREAT POINT PARTNERS LLC's 39 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ADMS | ADAMAS PHARMACEUTICALS INC | $31,932,000 | +4.7% | 2,109,099 | 0.0% | 9.14% | -16.4% | |
CNXR | CONNECTURE INC | $9,328,000 | -11.7% | 4,127,232 | 0.0% | 2.67% | -29.6% | |
AUPH | AURINIA PHARMACEUTICALS INC | $7,192,000 | +0.1% | 2,457,144 | 0.0% | 2.06% | -20.2% | |
BVX | BOVIE MEDICAL CORP | $4,395,000 | -1.8% | 2,680,000 | 0.0% | 1.26% | -21.6% | |
ARDMQ | ARADIGM CORP | $4,383,000 | -1.6% | 1,002,962 | 0.0% | 1.26% | -21.5% | |
OCRX | OCERA THERAPEUTICS INC | $3,731,000 | -35.4% | 1,963,777 | 0.0% | 1.07% | -48.5% | |
TENX | TENAX THERAPEUTICS INC | $2,838,000 | +24.9% | 1,108,593 | 0.0% | 0.81% | -0.4% | |
STRM | STREAMLINE HEALTH SOLUTIONS | $182,000 | -15.0% | 151,611 | 0.0% | 0.05% | -32.5% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-06-05 |
13F-HR | 2024-05-15 |
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.